<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069341</url>
  </required_header>
  <id_info>
    <org_study_id>FVF 4297s</org_study_id>
    <nct_id>NCT01069341</nct_id>
  </id_info>
  <brief_title>Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery</brief_title>
  <official_title>Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bhagat, Neelakshi, M.D., M.P.H.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bhagat, Neelakshi, M.D., M.P.H.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety of ranibizumab: a) as a surgical
      adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR)
      induced rubeosis and, b) in treatment of proliferative diabetic retinopathy (PDR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in
      diabetic subjects presenting initially with dense cataract and proliferative diabetic
      retinopathy induced rubeosis. Ten subjects will be enrolled at a single center over a 10
      month period. Patients will be followed for a total of 12 months in the treatment phase and
      will have safety follow-ups at Months 18 and 24. Eligibility for study entry will be
      determined by the principal investigator.

      Consented, enrolled subjects will receive multiple open-label intravitreal injections of 0.5
      mg ranibizumab administered every month for 3 doses (loading dose on Day 0 and at Months 1
      and 2) followed by as needed re-treatment based on specified criteria for the remainder of
      the study period. Subjects can receive a maximum of eight injections of ranibizumab during
      the study. All subjects will undergo cataract surgery after the first ranibizumab injection.
      Only one eye will be designated as the study eye for the duration of the study to receive the
      ranibizumab injections.

      All subjects will be evaluated with best corrected Early Treatment Diabetic Retinopathy Study
      (ETDRS) visual acuity, intraocular pressure measurement, ophthalmological examination, slit
      lamp photography, gonioscopy, fundus photography, fundus fluorescein angiography and Optical
      Coherence Tomography (OCT). An ultrasound will be done as needed. Best corrected ETDRS visual
      acuity and intraocular pressure measurements will be performed on both eyes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>first 12 months</time_frame>
    <description>Incidence and severity of AEs that were cataract surgery related (for instance, hyphema and vitreous hemorrhage) and AEs that occurred during the treatment of proliferative diabetic retinopathy (PDR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Neovascularization of Iris (NVI) or Neovascularization of the Angle (NVA)</measure>
    <time_frame>months 3, 7 and 12</time_frame>
    <description>Presence of neovascularization of iris (NVI) or neovascularization of the angle (NVA) as assessed by gonioscopy at months 3, 7 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Proliferative Diabetic Retinopathy (PDR)</measure>
    <time_frame>at month-12</time_frame>
    <description>Presence of proliferative diabetic retinopathy by fluorescein angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular Volume</measure>
    <time_frame>at months-1,3,7, and 12</time_frame>
    <description>Macular volume (millimeters cubed [mm3]) by Stratus OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to Re-treatment</measure>
    <time_frame>first 12 months</time_frame>
    <description>Mean time to re-treatment following the initial three monthly loading doses of ranibizumab (months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Ranibizumab Injections</measure>
    <time_frame>first 12 months</time_frame>
    <description>Mean number of ranibizumab injections required through month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of PRP Laser Treatments</measure>
    <time_frame>first 12 months</time_frame>
    <description>Mean number of PRP laser treatments required through month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Intraocular Pressure (IOP)</measure>
    <time_frame>at months-3,7, and 12</time_frame>
    <description>Mean change in IOP (mm Hg) from baseline to months-3, 7, and 12.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Rubeosis Iridis</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects enrolled received treatment with identical dosage of Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over

          -  Subjects with diabetes mellitus

          -  Subjects with proliferative diabetic retinopathy induced rubeosis

          -  Be willing to undergo cataract surgery

          -  HgbA1c level &lt; 12%

        Exclusion Criteria:

          -  History of glaucoma surgery

          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis

          -  Intraocular surgery in the study eye within 60 days preceding Day 0

          -  History of prior pars plana vitrectomy in the study eye

          -  Positive pregnancy test

          -  HbA1c &gt;12
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neelakshi Bhagat, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>NJMS / UMDNJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Njms / Umdnj</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <results_first_submitted>July 25, 2012</results_first_submitted>
  <results_first_submitted_qc>September 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2012</results_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rubeosis</keyword>
  <keyword>Neovascularization of iris</keyword>
  <keyword>Proliferative diabetic retinopathy</keyword>
  <keyword>PDR</keyword>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the patients seen in the Ophthalmology Department at the University of Medicine and Dentistry of New Jersey.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects With Treatment</title>
          <description>All subjects received o.5 mg of ranibizumab injections monthly for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects With Treatment</title>
          <description>All subjects received o.5 mg of ranibizumab injections monthly for 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event (AE)</title>
        <description>Incidence and severity of AEs that were cataract surgery related (for instance, hyphema and vitreous hemorrhage) and AEs that occurred during the treatment of proliferative diabetic retinopathy (PDR).</description>
        <time_frame>first 12 months</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE)</title>
          <description>Incidence and severity of AEs that were cataract surgery related (for instance, hyphema and vitreous hemorrhage) and AEs that occurred during the treatment of proliferative diabetic retinopathy (PDR).</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Neovascularization of Iris (NVI) or Neovascularization of the Angle (NVA)</title>
        <description>Presence of neovascularization of iris (NVI) or neovascularization of the angle (NVA) as assessed by gonioscopy at months 3, 7 and 12</description>
        <time_frame>months 3, 7 and 12</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Neovascularization of Iris (NVI) or Neovascularization of the Angle (NVA)</title>
          <description>Presence of neovascularization of iris (NVI) or neovascularization of the angle (NVA) as assessed by gonioscopy at months 3, 7 and 12</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Proliferative Diabetic Retinopathy (PDR)</title>
        <description>Presence of proliferative diabetic retinopathy by fluorescein angiogram</description>
        <time_frame>at month-12</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Proliferative Diabetic Retinopathy (PDR)</title>
          <description>Presence of proliferative diabetic retinopathy by fluorescein angiogram</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Macular Volume</title>
        <description>Macular volume (millimeters cubed [mm3]) by Stratus OCT</description>
        <time_frame>at months-1,3,7, and 12</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Volume</title>
          <description>Macular volume (millimeters cubed [mm3]) by Stratus OCT</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>Macular volume (millimeters cubed)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.47" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time to Re-treatment</title>
        <description>Mean time to re-treatment following the initial three monthly loading doses of ranibizumab (months)</description>
        <time_frame>first 12 months</time_frame>
        <population>All subjects' data was included</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Re-treatment</title>
          <description>Mean time to re-treatment following the initial three monthly loading doses of ranibizumab (months)</description>
          <population>All subjects' data was included</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Ranibizumab Injections</title>
        <description>Mean number of ranibizumab injections required through month 12</description>
        <time_frame>first 12 months</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Ranibizumab Injections</title>
          <description>Mean number of ranibizumab injections required through month 12</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>Number injections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of PRP Laser Treatments</title>
        <description>Mean number of PRP laser treatments required through month 12</description>
        <time_frame>first 12 months</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of PRP Laser Treatments</title>
          <description>Mean number of PRP laser treatments required through month 12</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>PRP Laser treatments</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Intraocular Pressure (IOP)</title>
        <description>Mean change in IOP (mm Hg) from baseline to months-3, 7, and 12.</description>
        <time_frame>at months-3,7, and 12</time_frame>
        <population>All subjects' data was analyzed, no subjects were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>0.5 mg ranibizumab, intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Intraocular Pressure (IOP)</title>
          <description>Mean change in IOP (mm Hg) from baseline to months-3, 7, and 12.</description>
          <population>All subjects' data was analyzed, no subjects were excluded</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>from baseline to month-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>from baseline to month-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>from baseline to month-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Month-24</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Subjects With Treatment</title>
          <description>All subjects received o.5 mg of ranibizumab injections monthly for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for congestive heart failure attributed to uncontrolled diabetes</sub_title>
                <description>2 months after 4th injection; 3 months after 4th injection: hospitalizations for CHF attributed to uncontrolled diabetes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization for hyperkalemia and CHF, attributed to renal insufficiency</sub_title>
                <description>2 months after 5th injection: hospitalization for hyperkalemia and CHF, attributed to renal insufficiency due to uncontrolled diabetes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization for exacerbation of CHF</sub_title>
                <description>4 months after 5th injection: hospitalization for exacerbation of CHF</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization for pleural effusion, CHF, and worsening of pre-existing foot ulcers (MRSA)</sub_title>
                <description>5 months after 5th injection: hospitalization for pleural effusion, CHF and worsening of pre-existing bilateral foot ulcers which cultures identified as MRSA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for flare-up of pre-existing gastritis</sub_title>
                <description>15 months after 3rd injection: hospitalization for flare-up of pre-existing gastritis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot amputation surgery pre-scheduled prior to enrollment</sub_title>
                <description>Hospitalization for a diabetic foot ulcer with a foot amputation scheduled prior to enrollment, 24 days after 1st injection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hospitalization for chronic osteomyelitis</sub_title>
                <description>14 months after 5th injection: hospitalization for chronic osteomyelitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for congestive heart failure and renal insufficiency</sub_title>
                <description>9 months after 3rd injection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Uncontrolled pilot study with a small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Neelakshi Bhagat</name_or_title>
      <organization>The University of Medicine and Dentistry of New Jersey</organization>
      <phone>973-972-2032</phone>
      <email>bhagatne@umdnj.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

